Edwards Lifesciences Co. (NYSE:EW) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Edwards Lifesciences Co. (NYSE:EW - Get Free Report) have been assigned a consensus recommendation of "Hold" from the twenty-six brokerages that are currently covering the stock, MarketBeat.com reports. Sixteen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $78.65.

A number of research firms have weighed in on EW. Evercore ISI dropped their target price on shares of Edwards Lifesciences from $76.00 to $70.00 and set an "in-line" rating on the stock in a research note on Tuesday, October 1st. Morgan Stanley reaffirmed an "equal weight" rating and issued a $70.00 price objective on shares of Edwards Lifesciences in a research note on Friday, October 11th. JPMorgan Chase & Co. increased their price target on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a "neutral" rating in a research report on Friday, October 25th. Daiwa America cut shares of Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 30th. Finally, Truist Financial reiterated a "hold" rating and issued a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm's stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,262,521.36. This trade represents a 9.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the firm's stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares of the company's stock, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 35,000 shares of company stock valued at $2,323,150. 1.29% of the stock is currently owned by insiders.

Institutional Trading of Edwards Lifesciences

A number of large investors have recently modified their holdings of EW. FSA Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the third quarter worth $30,000. Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences in the third quarter valued at $32,000. Avior Wealth Management LLC boosted its stake in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after acquiring an additional 308 shares in the last quarter. HHM Wealth Advisors LLC acquired a new position in Edwards Lifesciences in the second quarter valued at $55,000. Finally, Peoples Bank KS acquired a new position in Edwards Lifesciences in the third quarter valued at $40,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded down $0.65 during trading on Friday, hitting $73.32. 3,092,539 shares of the stock were exchanged, compared to its average volume of 4,642,550. Edwards Lifesciences has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a fifty day moving average price of $69.42 and a 200-day moving average price of $73.99. The stock has a market capitalization of $43.24 billion, a price-to-earnings ratio of 10.58, a price-to-earnings-growth ratio of 3.63 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts' consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter last year, the firm earned $0.59 earnings per share. Edwards Lifesciences's quarterly revenue was up 8.9% on a year-over-year basis. As a group, equities analysts predict that Edwards Lifesciences will post 2.56 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.